U.S. Markets open in 7 hrs 18 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
294.08+6.16 (+2.14%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close287.92
Bid0.00 x 0
Ask0.00 x 0
Day's Range290.29 - 296.91
52 Week Range244.28 - 329.83
Avg. Volume1,430,753
Market Cap62.18B
PE Ratio (TTM)18.42
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals14 hours ago

    ​Biogen gains $1B in value after Goldman Sachs touts Alzheimer’s drug

    Biogen Inc. gained more than $1 billion in market value Wednesday morning after Goldman Sachs, one of the world’s largest investment banks, added the drug developer to its closely-watched Equity Conviction List. Goldman Sachs analysts Terence Flynn and Cameron Bradshaw issued a research note this morning announcing that Cambridge-based Biogen (BIIB) was added to the list, which is essentially a strong recommendation to general investors to buy stock in a certain company. In their research note, Flynn and Bradshaw pointed specifically to Biogen’s experimental drug to treat Alzheimer’s disease, called aducanumab, as a prime reason for the company’s inclusion on the list.

  • CNBC15 hours ago

    Goldman has a new favorite biotech because of potential Alzheimer's blockbuster

    Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.

  • Barrons.com16 hours ago

    Biogen: Goldman Has Conviction!

    Biogen (BIIB) has had a good, though not great year. Is it time to add it to your portfolio? Shares of Biogen have gained 11.5% so far this year, and while that's better than the S&P 500's 10.3% rise during ...